Press release

Myomo® Announces Participation in Beijing Trade Show

Sponsored by Businesswire

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable
medical robotics company that offers increased functionality for those
suffering from neurological disorders and upper limb paralysis,
announces its participation in the China International Fair for Trade in
Services, to be held in Beijing from May 28-31, 2019. Myomo will
participate in this event together with Beijing Ryzur Medical Investment
Co., Ltd. (Ryzur Medical), a growing medical device manufacturer based
in Beijing.

Paul R. Gudonis, Chairman and CEO of Myomo, said, “We are already
positioned to provide our powered arm braces to individuals in North
America and selected markets in Europe, and Asia represents another
major region with a large population of patients with arm and hand
paralysis. By attending this event with Ryzur Medical, we are beginning
the process of exploring the potential to address this important future
market for Myomo. We are eager to learn more about the opportunity in
China and to continue toward our goal of becoming the worldwide standard
of care for upper extremity paralysis.”

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers expanded
mobility for those suffering from neurological disorders and upper limb
paralysis. Myomo develops and markets the MyoPro product line. MyoPro is
a powered upper limb orthosis designed to support the arm and restore
function to the weakened or paralyzed arms of patients suffering from
CVA stroke, brachial plexus injury, traumatic brain or spinal cord
injury, ALS or other neuromuscular disease or injury. It is currently
the only marketed device that, sensing a patient’s own EMG signals
through non-invasive sensors on the arm, can restore an individual’s
ability to perform activities of daily living, including feeding
themselves, carrying objects and doing household tasks. Many are able to
return to work, live independently and reduce their cost of care. Myomo
is headquartered in Cambridge, Massachusetts, with sales and clinical
professionals across the U.S. and representatives internationally. For
more information, please visit

About Beijing Ryzur Medical Investment Co., Ltd.

Ryzur Medical is a comprehensive provider that integrates medical
technology and services, medical equipment, medical services, and
medical investment.

At present, the company is divided into two business units: high-end
rehabilitation medical technology and equipment supply and professional
medical services. In terms of medical services, Ryzur Medical currently
directly manages five hospitals and provide rehabilitation medical
technical services and medical services.

Ryzur Medical also provides more than 200 models of rehabilitation
medical equipment in seven product lines, including orthopedic
rehabilitation, neurological rehabilitation, rehabilitation assessment
and physical therapy. The company owns the world-leading Non-Surgical
Spinal Decompression System (SDS) technology. Ryzur Medical has strict
requirements on production process and quality. All medical equipment
undergoes strict standard procedure testing and performance monitoring
before it leaves the factory. Ryzur Medical pursues zero-defect quality
and zero-complaint service. For more information, please visit

Forward Looking Statements
This press release contains
forward-looking statements regarding the Company’s future business
expectations which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, our potential future
business in Asia. These forward-looking statements are only predictions
and may differ materially from actual results due to a variety of
factors. Our actual results could differ materially from those
anticipated in these forward looking statements for many reasons,
including, without limitation, risks related to regulatory approval and
market acceptance of our products, our ability to secure and maintain
reimbursement for our products, our ability to obtain additional funding
to sustain and grow our business, and the other risk factors contained
in our filings made with the Securities and Exchange Commission. More
information about factors that potentially could affect Myomo’s business
and financial results is included in Myomo’s filings with the Securities
and Exchange Commission. The Company cautions readers not to place undue
reliance on any such forward-looking statements, which speak only as of
the date made. The Company disclaims any obligation subsequently to
revise any forward-looking statements to reflect events or circumstances
after the date of such statements or to reflect the occurrence of
anticipated or unanticipated events.